1. Executive Summary
1.1. Global Toxoplasmosis Testing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Toxoplasmosis Testing Market Outlook, 2018 - 2031
3.1. Global Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Serological Tests
3.1.1.1.1. Dye Tests
3.1.1.1.2. Indirect Hemagglutination Assays
3.1.1.1.3. Direct Agglutination Assays
3.1.1.2. ELISA
3.1.1.3. PCR
3.1.1.4. Ultrasound
3.1.1.5. MRI
3.1.1.6. Biopsy
3.2. Global Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Blood Samples
3.2.1.2. Amniotic Fluid
3.2.1.3. Cerebrospinal Fluid
3.3. Global Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospitals
3.3.1.2. Clinics
3.3.1.3. Diagnostic Laboratories
3.4. Global Toxoplasmosis Testing Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Toxoplasmosis Testing Market Outlook, 2018 - 2031
4.1. North America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Serological Tests
4.1.1.1.1. Dye Tests
4.1.1.1.2. Indirect Hemagglutination Assays
4.1.1.1.3. Direct Agglutination Assays
4.1.1.2. ELISA
4.1.1.3. PCR
4.1.1.4. Ultrasound
4.1.1.5. MRI
4.1.1.6. Biopsy
4.2. North America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Blood Samples
4.2.1.2. Amniotic Fluid
4.2.1.3. Cerebrospinal Fluid
4.3. North America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospitals
4.3.1.2. Clinics
4.3.1.3. Diagnostic Laboratories
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Toxoplasmosis Testing Market Outlook, 2018 - 2031
5.1. Europe Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Serological Tests
5.1.1.1.1. Dye Tests
5.1.1.1.2. Indirect Hemagglutination Assays
5.1.1.1.3. Direct Agglutination Assays
5.1.1.2. ELISA
5.1.1.3. PCR
5.1.1.4. Ultrasound
5.1.1.5. MRI
5.1.1.6. Biopsy
5.2. Europe Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Blood Samples
5.2.1.2. Amniotic Fluid
5.2.1.3. Cerebrospinal Fluid
5.3. Europe Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Clinics
5.3.1.3. Diagnostic Laboratories
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Toxoplasmosis Testing Market Outlook, 2018 - 2031
6.1. Asia Pacific Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Serological Tests
6.1.1.1.1. Dye Tests
6.1.1.1.2. Indirect Hemagglutination Assays
6.1.1.1.3. Direct Agglutination Assays
6.1.1.2. ELISA
6.1.1.3. PCR
6.1.1.4. Ultrasound
6.1.1.5. MRI
6.1.1.6. Biopsy
6.2. Asia Pacific Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Blood Samples
6.2.1.2. Amniotic Fluid
6.2.1.3. Cerebrospinal Fluid
6.3. Asia Pacific Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Clinics
6.3.1.3. Diagnostic Laboratories
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Toxoplasmosis Testing Market Outlook, 2018 - 2031
7.1. Latin America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Serological Tests
7.1.1.1.1. Dye Tests
7.1.1.1.2. Indirect Hemagglutination Assays
7.1.1.1.3. Direct Agglutination Assays
7.1.1.2. ELISA
7.1.1.3. PCR
7.1.1.4. Ultrasound
7.1.1.5. MRI
7.1.1.6. Biopsy
7.2. Latin America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
7.2.1.1. Blood Samples
7.2.1.2. Amniotic Fluid
7.2.1.3. Cerebrospinal Fluid
7.3. Latin America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Clinics
7.3.1.3. Diagnostic Laboratories
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Toxoplasmosis Testing Market Outlook, 2018 - 2031
8.1. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Serological Tests
8.1.1.1.1. Dye Tests
8.1.1.1.2. Indirect Hemagglutination Assays
8.1.1.1.3. Direct Agglutination Assays
8.1.1.2. ELISA
8.1.1.3. PCR
8.1.1.4. Ultrasound
8.1.1.5. MRI
8.1.1.6. Biopsy
8.2. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Blood Samples
8.2.1.2. Amniotic Fluid
8.2.1.3. Cerebrospinal Fluid
8.3. Middle East & Africa Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Clinics
8.3.1.3. Diagnostic Laboratories
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Toxoplasmosis Testing Market by Test Type, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Toxoplasmosis Testing Market by Sample, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Toxoplasmosis Testing Market by End User, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By End User vs by Sample Heatmap
9.2. Manufacturer vs by Sample Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Abbott Laboratories
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Bio-Rad Laboratories Inc
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Amazon Renewed
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Affymetrix Inc.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Beckman Coulter Inc.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Biotest
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Cepheid Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. GenBio
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Danaher Corporation
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Thermo Fisher Scientific
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Biomerica Inc.
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Biomerix
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations